Hemopure News
Most Popular Hemopure Story
Expert panel rejects pleas for Hemopure trial
Rejecting the strenuous pleas of the U.S. Navy, an FDA advisory panel has rejected Biopure's bid to test the blood substitute Hemopure on civilian trauma patients. Voting 11 to eight against the move, the experts concluded that the risks exceeded the potential benefits of the trial. Blood substitutes are a highly controversial therapy, in large part because they need to be tested on trauma victims without their consent. The Navy has been backing Biopure's program, though, saying that a …
... Read more...Latest Headlines
- October 8, 2009
- August 8, 2008
- July 8, 2008
- December 14, 2006
- December 14, 2006
- July 13, 2006
- July 10, 2006
- July 5, 2006
- October 18, 2005
- July 11, 2005
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
